
Table of Contents:
1. mRNA vaccines: how they work, efficacy, side effects and other Q&A ......................................................... 2
2. Vector vaccines: how they work ......................................................................................................................... 4
3. Select vaccine candidates using recombinant proteins ....................................................................................... 5
4. Select vaccine candidates using attenuated viruses ............................................................................................ 6
5. Long term health issues for COVID survivors .................................................................................................. 7
6. Testing for antibodies ........................................................................................................................................... 9
7. Tracking antibodies in COVID survivors ........................................................................................................ 10
8. T-cells and COVID ............................................................................................................................................... 11
9. Progression of the virus ...................................................................................................................................... 12
10. Testing for the presence of the virus .............................................................................................................. 13
11. PCR testing caveats and shortfalls .................................................................................................................. 14
12. Update on anti-viral, immunomodulator and corticosteroid trials ................................................................. 15
13. Convalescent plasma and monoclonal antibody therapy ................................................................................ 17
14. Possible benefits of anticoagulants, statins and ACE inhibitors for infected patients .............................. 19
mRNA vaccines: how they work, efficacy, side effects and other Q&A

How do mRNA vaccines work?

Messenger RNA is a single-stranded molecule present in all cells. It carries instructions for making proteins from the cell nucleus to the cytoplasm, which in turn translates information stored in mRNA and makes proteins. Rather than injecting the virus or a viral protein (which is a part of the virus), an mRNA vaccine contains genetic material that encodes the viral protein. When these genetic instructions are injected into the arm, muscle cells translate them and make the viral protein directly in the body. This gives the immune system a preview of what the real virus looks like, allowing it to generate antibodies and T-cells that can fight the virus if the individual is infected. mRNA are packaged inside lipid nanoparticles to prevent them from being immediately destroyed by the body’s immune system; eventually, the body’s enzymes degrade the mRNA after it delivers its instructions.

Moderna and Pfizer mRNA vaccines for COVID are the first mRNA vaccines ever approved in Western countries. As shown below, 60% of the current vaccine market is made up of recombinant protein vaccines (which we discuss later), with the rest mostly divided between the two attenuated virus types. As for COVID vaccines under development, they were more evenly split by type as of April 2020.

What does vaccine efficacy mean?

Phase III results from Moderna and Pfizer trials point to 80%-90% “efficacy”, which measures the difference between incidence of disease in placebo (P) and vaccinated (V) cohorts. In other words, efficacy is computed as (P-V)/P. While the residual number of vaccinated patients still got COVID (i.e., the people upon who the vaccine was not “effective”), in most trials conducted to date none of these people died, or required hospitalization or supplemental oxygenation. In other words, vaccines appeared to substantially mitigate COVID severity even when people still became sick.

However, trials are just that: a small sample size relative to the millions of people that will be vaccinated. Some things to keep in mind:

- In some trials (i.e., Pfizer), large numbers of “suspected” COVID cases were not included when vaccine subjects had a negative PCR. If the suspected cases were included, reported efficacy numbers could drop substantially. As a reminder, PCR sensitivity (the ability of a PCR test to identify disease in an infected person) ranges from 87.5%-100%, meaning that such tests can produce false negatives.

- Most trials excluded pregnant women, children and people with certain immune disorders

- Trials cannot test all the permutation of clinical and behavioral conditions which exist in broad populations

As a result, the best way to monitor efficacy is through the actual infection, hospitalization and mortality results in populations that have received the vaccines.
What about side effects?

The CDC maintains a website of historical vaccine safety concerns and outcomes starting in 1955 which you can access here: https://www.cdc.gov/vaccinesafety/concerns/concerns-history.html.

The CDC also maintains a database of self-reported adverse events from all vaccines (VAERS). We found that incidence of hospitalization and emergency room visits after COVID vaccines is higher than for the flu, but still very low on an absolute basis and similar to other vaccines and medications. The challenge with this data is that it is not “causal”; adverse events need more analysis to determine if they were actually caused by the vaccine or not. But in the spirit of full disclosure, here’s the data we compiled using VAERS data.

VACCINE SIDE EFFECTS: COVID vs INFLUENZA

<table>
<thead>
<tr>
<th>Side Effect</th>
<th>COVID #</th>
<th>COVID Freq</th>
<th>COVID # per mm</th>
<th>INFLU #</th>
<th>INFLU Freq</th>
<th>INFLU # per mm</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hospitalized</td>
<td>25268</td>
<td>0.0077%</td>
<td>76.8</td>
<td>370</td>
<td>0.0002%</td>
<td>2.1</td>
</tr>
<tr>
<td>Disability</td>
<td>5950</td>
<td>0.0018%</td>
<td>18.1</td>
<td>176</td>
<td>0.0001%</td>
<td>1.0</td>
</tr>
<tr>
<td>Dr office visit</td>
<td>84094</td>
<td>0.0256%</td>
<td>255.8</td>
<td>2842</td>
<td>0.0016%</td>
<td>16.3</td>
</tr>
<tr>
<td>ER visit</td>
<td>58449</td>
<td>0.0178%</td>
<td>177.8</td>
<td>1073</td>
<td>0.0006%</td>
<td>6.1</td>
</tr>
</tbody>
</table>


Other vaccine adverse event data:

- Smallpox: 14-52 life-threatening events per mm, encephalitis 12 per mm
- Shingles: 40 serious adverse events per mm
- Measles, mumps, rubella: febrile seizure 850 per mm

Would an mRNA vaccine alter my DNA?

Scientific consensus: No. Simplified answer: “Think of RNA as a bunch of messages. At any moment a human cell has 5,000+ different RNA messages, and they are all temporary messages, like post-it notes that get torn up by the cells within minutes or hours after being read. Or, actually, like snapchat messages that expire. Temporary messages instructing cells to make one viral protein temporarily, so that it provokes an antibody response”.¹

Technical answer: mRNA is downstream of the DNA genetic material and all of its editing and replication. Just like the coronavirus itself is not altering your genetic material (it’s also made of RNA), neither would the Pfizer or Moderna vaccines. In contrast, HIV is also a single-stranded RNA virus but is also a “retrovirus”, meaning that it carries RNA to make reverse transcriptase, which it then uses to make DNA from its RNA, and subsequently integrate itself into the host genome. But this is not the case with the coronavirus or the mRNA vaccines being developed to treat it.²

What about DNA messenger vaccines?

RNA vaccines have advantages over DNA vaccines: their payloads both enter human cells, but DNA vaccines have to go further and deliver to the nucleus as well. Being DNA, there’s also an outside chance for such external sequences to get incorporated into a cell’s own genetic material, which isn’t possible with RNA. The RNA platform is the better of the two, reflected in the relative amounts of effort that have gone into each.

¹ Shane Crotty, La Jolla Institute for Immunology
² Lior Pachter, CalTech, Division of Biology and Biological Engineering
Are there other mRNA vaccines under development?

CureVac, a German biopharmaceutical company, is developing an mRNA vaccine and entered Phase 2b/3 trials in December 2020 with 36,500 participants in Europe and Latin America. The only available data is preclinical trial data in mice which showed that the vaccine was effective in producing neutralizing antibodies in all doses. CureVac will provide the EU with 225 million doses and expects to manufacture 300 million doses in 2021. The company has reportedly collaborated with Tesla to create mRNA “micro-factories” which could help produce more doses (Source: NYT).

Vector vaccines: how they work

Vector vaccines are also “genetic” but they work differently. Vector vaccines use a “Trojan Horse” approach to deliver genetic instructions to the body’s cells: the process involves the use of a virus different from SARS-CoV-2 to “infect” cells with the gene for SARS-CoV-2 spike proteins (i.e., only the spike protein and not the virus itself; you cannot get COVID from the spike protein alone). Once these genes are injected via vaccine, the body transcribes the genes into mRNA, which in turn prompts the cell’s cytoplasm to produce the SARS-CoV-2 spike proteins which provoke an antibody response (i.e., the latter step is the same as for the mRNA vaccines).

Oxford’s vector vaccine uses a chimpanzee virus that is altered to be harmless to humans, and for which humans have no antibodies. Update: In early April, a UK regulatory agency announced that the Oxford/AstraZeneca vaccine should not be administered to patients under age 30 due to evidence suggesting a link between the vaccine and blood clots.

J&J’s vaccine uses a vector approach as well, but with a human adenovirus as the carrier. The adenovirus is altered to be non-replicating, effectively preventing it from causing adenovirus infections. Update: In late April, the CDC recommended use of J&J vaccines following a temporary pause which was implemented in order to investigate linkages between the vaccine and blood clots.

CanSino is also developing a vector vaccine (AD5-nCov) which uses an altered live adenovirus to deliver the SARS-CoV-2 spike proteins into the body. Unlike Oxford and J&J, CanSino is using a virus that humans have already been exposed to. CanSino initiated Phase III trials in August 2020, and initial results indicate an efficacy rate of 65% in preventing symptomatic COVID cases. Like J&J, CanSino’s vaccine only requires one dose, but the company is considering the use of a booster shot in light of evidence that the efficacy of the vaccine could wane over time.

Genetic vaccines: the future

Genetic vaccines are a remarkable breakthrough, particularly compared to traditional vaccine types made from attenuated viruses and recombinant proteins. Both development timelines and the time required to address evolving mutations and variants are much faster for genetic vaccines. However, there’s a big unknown: the risk of declining efficacy as the human body starts to recognize delivery mechanisms of genetic vaccines, attacking them before they have a chance to complete their mission. This is very unlikely to be a problem for annually delivered vaccines with small doses for diseases like COVID, but could become an issue for more frequent treatment applications with much larger doses (i.e., weekly delivery with doses that are 800x higher than those used in COVID vaccines).

Genetic vaccines package instructions inside something else: in the case of vector vaccines, adenoviruses or chimpanzee viruses that are harmless to humans; and in the case of mRNA vaccines, cationic phospholipids. The word “cationic” is important; neutral lipids would not provoke the body’s immune system, but lipids used for mRNA vaccines are positively charged (cationic) to offset the negative charge of the RNA. On its own, negatively charged RNA would be destroyed by the immune system, but positively charged lipids appear to eventually be recognized by the immune system as well. Moderna wrote a paper about this in 20193, citing increased antibody responses to the lipid surface coating and the structural lipid layer. To reiterate, this issue pertains to very high-

---

3 “Accelerated Blood Clearance of Lipid Nanoparticles Entails a Biphasic Humoral Response of B-1 Followed by B-2 Lymphocytes to Distinct Antigenic Moieties”, Besin et al, Moderna Inc. June 2019
frequency therapeutic treatments with very large dosages, and should not be an issue for annual treatments with small dosages such as COVID vaccines.

**Select vaccine candidates using recombinant proteins**

Vaccine manufacturers that focus on attenuated and recombinant protein vaccine technologies have a longstanding track record of providing long lasting and safe immunity. Today, state-of-the-art preventive vaccines based on recombinant proteins represent 60% of all vaccines on the market. As these vaccines are produced in controlled bioreactors outside of the body, their structure and purity can be measured and calibrated. In contrast, “genetic” vaccines (DNA and RNA) are providing a genetic *template* to the body which then produces the proteins that trigger an antibody response. Once genetic vaccines are administered to the body, their destination and their protein-generating activity cannot be as tightly controlled.

The disadvantage of recombinant vaccines is the time it takes to develop customized cell lines (bioreactors) to produce a uniform and stable vaccine protein structure. Bioreactors can be based on bacterial, yeast, insect, plant and mammalian systems. Once the cell lines are developed, they can often be scaled quickly and cheaply. The end product: a vaccine that is a partial replica of the virus protein. Once the vaccine protein is administered to the body, the immune system is trained so that if confronted with the *real* virus, antibodies and memory cells are prepared to fight it.

Another complexity: bioreactors based on insect or plant life might produce virus proteins that are not identical to those the body confronts with the actual disease. As a result, antibody responses to some recombinant protein vaccines are sometimes sub-optimal, and require the addition of an “adjuvant” to provoke a stronger antibody response. Some vaccines under development attempt to get around this by using mammalian cells as bioreactors; we expect to know more later in the year as they begin Phase I/II trials.

**Novavax** launched trials for its protein-based vaccine in May 2020 and received $1.6 billion in federal funding for development and manufacturing. Prior to COVID, the company had not delivered a vaccine to market. Novavax announced trial data from its UK Phase III trial in March 2021, which demonstrated 96% efficacy against the original coronavirus strain, but only 49% vs the South Africa variant. The company is reportedly developing a new vaccine tailored to this variant. In June 2021, after delays caused by manufacturing issues, Novavax released data on its Phase III trial in the US and Mexico, which demonstrated 93% efficacy against variants considered “variants of concern” or “variants of interest”. Novavax expects to receive regulatory approval in the US and UK no earlier than July 2021, and expects to distribute 150 million doses per month by Q4 2021.

**Sanofi/GlaxoSmithKline** accelerated development of a vaccine based on delivery of SARS-CoV-2 spike proteins into humans, a process designed to engender an antibody response. Their existing Flu-Blok process (approved in 2013) would work as follows: take the genetic sequence of the SARS-CoV-2 virus, splice it into an insect virus and wait for cells from insects (moths, actually) to generate SARS-CoV-2 spike proteins, which are then injected into humans. GSK’s “adjuvant” of organic chemicals is added to provoke an even stronger immune response (small amounts of aluminum have been used in vaccines since the 1930’s for this reason). Sanofi/GSK initiated Phase I/II trials in September 2020, but suffered a setback in December. The company announced that while antibody responses from their vaccine were similar to recovered COVID patients, this only held true for trial participants aged 18-49. For participants over 50, the immune response was lower, possibly due to an insufficient concentration of the antigen. The company has reformulated its vaccine approach and launched a new Phase II trial of 720 participants in February 2021, aiming to produce its vaccine in Q4 2021.
Select vaccine candidates using attenuated viruses

Unlike genetic vaccines and recombinant protein vaccines, attenuated vaccines contain the entire SARS-CoV-2 virus. The virus is chemically modified to inactivate it so that it cannot cause disease. There are two different types of attenuated vaccines: live and inactivated. Live attenuated vaccines elicit strong immune responses but are not suitable for people with weakened immune systems. In an inactivated vaccine, the virus is killed so that it is unable to replicate. Inactivated vaccine responses are usually not as strong as live vaccines, so booster shots are often used to ensure ongoing protection.

**Sinovac**’s vaccine is an inactivated virus vaccine with an adjuvant. In the Phase I trial, no severe side effects were reported but only 80% of participants showed neutralizing antibodies. 95-99% of participants showed neutralizing antibodies in the Phase II trial, however the antibody levels (“titers”) were lower than those seen in recovered coronavirus patients. Phase III trials in 25,000 participants across Brazil, Indonesia, Turkey and Chile demonstrated efficacy of 50.65% in preventing all cases, but was 100% effective in preventing severe cases, hospitalizations or deaths. In the trials based in Turkey, the vaccine had an efficacy rate of 91.25%.

**SinoPharm**’s vaccine candidate is based on an inactivated virus. Phase I trials demonstrated only mild adverse reactions, and the Phase II trial showed the vaccine produced antibodies in 98% of participants. SinoPharm moved forward with a dosage protocol based on the highest safety data and lowest antibody response of all the protocols examined in Phase I. As with most vaccine candidates, the dosage protocol requires a second booster shot. In July 2020, SinoPharm began its Phase III trial in the U.A.E. with 31,000 participants, and announced an efficacy rate of 86%, leading the UAE and several other countries to authorize the vaccine for use. In May 2021, a WHO panel reported that Sinopharm had a 79% efficacy rate according to trial data from UAE, China, Bahrain, Egypt and Jordan. Due to efficacy concerns against emerging variants, the UAE and Bahrain announced it would provide a third shot to fully vaccinated individuals.

**Covaxin**’s vaccine candidate, also based on an inactivated virus, was developed by India-based Bharat Biotech in partnership with Ocugen, a US biopharmaceutical company. The vaccine entered Phase III trials in October 2020 after Phase I/II trials demonstrated safety and production of antibodies. Interim results from their Phase III trials among 25,000 volunteers showed the vaccine demonstrated 78% overall efficacy and 100% efficacy against severe infection. The vaccine has been approved for emergency use in India and several other countries.
Long term health issues for COVID survivors

Lingering health consequences of COVID can be very debilitating for survivors of all ages: lung scarring, heart damage (cardiomyopathy and myocarditis), neurocognitive problems and abnormal blood clotting. While over 90% of influenza patients recover fully within two weeks, COVID damage is apparently longer-lasting: CDC surveys show that 20% of those aged 18-34 experienced lasting symptoms.

Bottom line: you do not want to get this disease, no matter your age. Some recent after-effect studies are shown below; more detailed source information is available on request.

Lung Scarring:
- A Chinese study of 70 hospitalized patients who were eventually discharged showed that 66 patients (94%) still had mild to substantial residual lung abnormalities on their last CT scans
- More than a third of 71 SARS patients infected in 2003 had reduced lung capacity 15 years later in 2018
- MERS: 36% of patients continued to show signs of lung damage through abnormal chest radiographs
- COVID-19 scarring rates may end up being higher than SARS and MERS patients since those illnesses often attacked only one lung; COVID-19 appears to affect both lungs

Blood clots:
- A French study of 100 patients with severe COVID-19 showed 23% of patients with acute pulmonary embolus (blockage in the lungs as a result of a blood clots forming in other parts of the body).
- 2% to 4% of such survivors may have chronic pulmonary hypertension (shortness of breath, decreased exercise ability, heart failure)

Heart damage:
- An early study of 41 hospitalized patients in January from Wuhan, China found 12% of Covid-19 patients had signs of cardiovascular damage. Another study in Wuhan found that 19% of hospitalized COVID-19 patients showed signs of cardiac injury
- COVID-19 may cause long-lasting cardiac damage which could increase risk for heart attack and stroke

Neurological problems:
- Neurological symptoms were seen in 36% of Chinese patients. When looking only at severe cases the incidence of neurological symptoms increased to 46%. Symptoms included dizziness, headaches, nerve pain, impaired consciousness, and impaired taste/smell/vision
- Longer-term consequences of COVID-19 could include lower levels of attention, concentration, and memory, as well as dysfunction in peripheral nerves
- A study of 62,000 COVID patients showed that 20% later developed a new mental illness such as anxiety, depression and insomnia

---

4 American Heart Association, University of Texas Health Science Center, Columbia University Dep’t of Neurology and Epidemiology, Tongji Medical College, Peking University People’s Hospital, United Arab Emirates College of Medicine and Health Sciences, USC Keck School of Medicine, Johns Hopkins Medicine, Centre Hospitalier Universitaire de Besancon, Renmin Hospital of Wuhan University, North Bristol NHS Trust (UK), Lancet Psychiatry Journal
Long term fatigue and breathlessness

- UK researchers examined 110 Covid-19 patients whose illnesses required hospital stays for a median of five days between March 30 and June 3. Twelve weeks after these patients were released from the hospital, 74% reported symptoms including breathlessness and excessive fatigue.

One assessment from the UK covers a variety of mild and more severe long term effects in people infected from April to December 2020, all measured 5 weeks after testing positive. The “any symptom” category results fell to 10% after 12 weeks. The results appear below.

![Bar chart showing long term symptoms by gender and category: Any symptom, Fatigue, Cough, Headache, Loss of taste/smell, Myalgia.](chart.png)

Source: U.K. Office for National Statistics
Note: April 22 to Dec. 14, 2020 survey; estimates based on unweighted data and assumes continuous symptoms among 9,063 respondents who ever tested positive for Covid-19 and were symptomatic at five weeks.
Testing for antibodies

Serology kits may differ on “specificity” (false anti-body positive) and “sensitivity” (false anti-body negative), in which case antibody presence could be misestimated\(^5\). A study from UC Berkeley analyzed 12 different serology tests, and provided some insight into these questions. The authors found “good to excellent sensitivity for all evaluated tests in hospitalized patients three or more weeks into their disease course”, and that their data “demonstrate specificity > 95% for the majority of tests evaluated, and > 99% for three of them”\(^6\). Roche announced that their serology test has 100% sensitivity and 99.8% specificity.

Serology tests: FDA caveats

There are over 50 companies that have informed the FDA of their intention to sell serology test kits in the US. Roche intends to ramp up production to the “high double digit” millions by June, which can be processed using their device with 300 results per hour. However, all kits are self-validated, and the FDA requires that the following disclosures be included:

- The tests have not been reviewed by the FDA
- Negative results do not rule out SARS-CoV-2 infection. Follow-up testing with a molecular diagnostic should be considered to rule out infection
- Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status
- Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains

These are strongly worded caveats, which some countries already appear prepared to disregard, or at least acknowledge as “acceptable” risk as the world focuses on getting back to work.

---

\(^5\) The higher the disease prevalence, the lower the false positive problem. In addition, actual negatives are much larger than false positives, so as a policy approach, serology tests correctly identify the majority of susceptible people.

Tracking antibodies in COVID survivors

A recent study from King’s College in London found that antibody levels declined in COVID survivors. Some news reports concluded that these findings raise the risk of reinfection for survivors. However, that’s a very premature judgment to make without knowing the answer to any of the following questions:

- What antibody levels are required to prevent reinfection? Just because antibody levels decline doesn’t mean that they will be below the threshold required. Even if the blood plasma of recovered Covid-19 patients does not have high antibody levels, it has still proven to be to sufficient to fend off the virus to some extent in vitro, and there is evidence that the body could produce more antibodies if needed.

- What antibody levels wouldn’t block reinfection, but would still reduce severity of the disease and render people asymptomatic? Again, another completely unknown quantity.

- Could T-cell reactivity be enough when combined with modest levels of antibodies? See next page for a discussion of T-cell responses to disease.

Duration of neutralizing antibodies by disease severity

Antibodies detected (ID₅₀), log scale


---

7 “The observation that plasma neutralizing activity is low in most convalescent individuals, but that recurrent anti-SARS-CoV-2 receptor binding domain (RBD) antibodies with potent neutralizing activity can be found in individuals with unexceptional plasma neutralizing activity suggests that humans are intrinsically capable of generating anti-RBD antibodies that potently neutralize SARS-CoV-2”. Source: “Convergent antibody responses to SARS-CoV-2 in convalescent individuals”, Robbiani et al, Rockefeller University. June 18, 2020.
T-cells and COVID

Antibodies are not the only weapon the body uses to fight viruses; T-cells play a role as well, often through a process called “lysis” in which invading pathogens are killed or weakened (“killer” T cells destroy virus-infected cells, while “helper” T cells assist in antibody production). This research is early-stage, but scientists now believe that a subset of people have T-cells that recognize SARS-CoV-2 even though they’ve never been exposed to it. Known as cross-reactive T-cells, these cells may give the body a head start in fighting SARS-CoV-2.

- To be clear, T-cells provide “cross reactive immune memory” rather than “immunity”. The distinction is critical; the latter implies iron-clad protection, while the former simply increases the prospects of less severe infection: “T cells generally don’t completely prevent infections, they limit disease (make it shorter and/or less serious). Thus, wearing a mask is much more effective than hoping you and the people around you have pre-existing T cell memory”

- Pre-existing T-cells that react to SARS-CoV-2 appear to result from past exposure to widely circulating “common cold” coronaviruses, and not from prior exposure to SARS-CoV-1, SARS-CoV-2 or MERS.

- T-cells are analyzed to see if they secrete interferon-gamma after being exposed to SARS-CoV-2 viral proteins, which is how they respond when recognizing the specific antigen that activates them

- A multi-disciplinary team from Singapore writing in Nature magazine found that ~50% of a random unexposed group had T-cells that responded to SARS-CoV-2 viral proteins (in people that recovered from SARS-CoV-2 and SARS-CoV-1, 100% of patient T-cells did). Their results are similar to a May La Jolla Institute study finding T-cell reactivity in 50% of blood donor samples dating from 2015 – 2018, and an April study from Berlin University finding T-cell reactivity in 34% of healthy blood donors.

- After SARS-CoV-1, antibodies faded in some patients. However, their T-cell responses to SARS were still robust 17 years later. This might explain the paradox of falling antibodies in recovering COVID patients and no reliable reports of reinfection. In other words…”that would argue that there has been past zoonotic coronavirus transmission in humans, unknown viruses that apparently did not lead to serious disease, which have provided some people with a level of T-cell based protection to the current pandemic”

### Proportion of subjects with T-cell responses to SARS-CoV-2 structural and non-structural proteins

<table>
<thead>
<tr>
<th></th>
<th>Unexposed</th>
<th>SARS-CoV-2</th>
<th>SARS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Structural proteins only</td>
<td>4 (11%)</td>
<td>24 (67%)</td>
<td>21 (91%)</td>
</tr>
<tr>
<td>Non-structural proteins only</td>
<td>8 (22%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
<tr>
<td>Structural and non-structural proteins</td>
<td>7 (19%)</td>
<td>12 (33%)</td>
<td>2 (9%)</td>
</tr>
<tr>
<td>Negative</td>
<td>18 (49%)</td>
<td>0 (0%)</td>
<td>0 (0%)</td>
</tr>
</tbody>
</table>


---

8 Shane Crotty, Vaccine Discovery Division at La Jolla Institute for Immunology, August 11, 2020
9 “SARS-CoV-2-Reactive T Cells Found in Patients with Severe COVID-19”, Scientist.com, July 30, 2020
11 “Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals”, Grifoni et al, La Jolla Institute for Immunology, May 14, 2020
13 “New Data on T Cells and the Coronavirus”, Derek Lowe, July 15, 2020
Progression of the virus

People that contract COVID-19 usually develop antibodies that most virologists believe will prevent them from getting sick again, although this assertion and the antibody levels required are still to be empirically proven. While other human coronaviruses that cause seasonal colds do not typically result in long-lasting immunity, SARS and MERS antibodies persisted for at least 2-3 years.

As shown on the left, by day 10, viral culture studies show that most people are no longer infectious. The viral decline is the direct result of the body’s immune response, part of which involves the appearance of virus-specific antibodies (“seroconversion”). A March study from Shenzhen provides one assessment. Using serology tests, they measured the presence of general virus antibodies (Ab), early stage immune response antibodies (Immunoglobulin M) and antibodies for long-lived immunity (Immunoglobulin G). Some patients’ antibodies appeared during the first week; more showed up in the second week; and after 15 days, 80%-100% of patient samples contained one or more classes of antibodies. Overall, they found strong empirical support for routine application of serological testing in the diagnosis and management of COVID-19 patients.

More recent studies confirm the appearance of antibodies and seroconversion. A July 2020 study from Harvard Medical School showed seroconversion after 11 days, and found that IgG antibodies were still detectable after 75 days.

Sources

“Antibody responses to SARS-CoV-2 in patients of novel coronavirus disease 2019”, Zhao et al, Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People’s Hospital, Shenzhen

“Neutralizing antibody responses to SARS-CoV-2 in a COVID-19 recovered patient cohort and their implications”, Fan Wu et al, Shanghai Public Health Clinical Center, Fudan University, March 30, 2020

“Dynamics and significance of the antibody response to SARS-CoV-2 infection,” Iyer et al. Harvard Medical School, July 20, 2020
Testing for the presence of the virus

- The data we have seen on testing accuracy is divided into PCR test results and Rapid test (antigen) results.
- Testing accuracy is typically measured by looking at its error rate, and there are two kinds of errors: false positives (people who aren’t sick but who are TOLD they are) and false negatives (people who ARE sick who are told they are fine). The false positive error is a productivity problem: people told to stay home when they could come to work. The false negative problem is worse: these individuals spread the virus since they don’t know they are ill.
- Neither PCR nor antigen tests have substantial false positive rates. That’s the good news. However, there’s a public health cost to rapid antigen tests since they have a much higher false negative rate than PCR tests.
- The table below shows the false positive and false negative rates for both PCR and antigen tests. Ranges differ by manufacturer, and over time; more recent tests are presumably more accurate.
- A false positive is different than a “high cycle” positive PCR test: in the former situation, someone isn’t sick and is told they are infected. In the latter situation, a person has the virus but is at the tail end and is no longer infectious to others, but since the PCR test still picks up traces of genetic material, the test comes back as being positive. The test isn’t wrong since they person had COVID, it’s just that they are no longer infectious. I am not aware of PCR testing protocols that allow for identification of “high cycle” individuals.
- As a reminder, none of the PCR or antigen tests have been certified for accuracy by the FDA. They have all been granted emergency use authorization due to the pandemic, but anyone tested should understand the risks inherent in the process.

<table>
<thead>
<tr>
<th>Diagnostic test</th>
<th>Method</th>
<th>Average “sensitivity”: ability to detect virus in infected people (failures = false negatives)</th>
<th>Average “specificity”: ability to confirm lack of infection in uninfected people (failures = false positives)</th>
<th>Indicative manufacturers</th>
</tr>
</thead>
<tbody>
<tr>
<td>PCR</td>
<td>Detect the virus genetic material</td>
<td>98.9% (87.5%-100%)</td>
<td>99.4% (92.3%-100%)</td>
<td>Abbott, Quidel, Roche, Thermo Fisher, LabCorp, Quest Diagnostics, Hologic</td>
</tr>
<tr>
<td>Antigen</td>
<td>Detect specific proteins on the surface of the virus</td>
<td>90.4% (80%-97.6%)</td>
<td>99.2% (96.6%-100%)</td>
<td>Abbott, Quidel, Becton Dickinson &amp; Company, Access Bio, LumiraDx</td>
</tr>
</tbody>
</table>

PCR testing caveats and shortfalls

A PCR test is not like a pregnancy test, which returns a simple yes/no result. PCR tests return a positive reading when a certain threshold of virus genetic material is found. And this is where it can get complicated: positive PCR (nasal swab) tests for the same person may differ depending on how “fine-tuned” the equipment is for evaluating them. As a result, reported infections could fall substantially if all equipment were calibrated similarly. Furthermore, some hospitalized individuals may be counted as COVID patients when they are in the hospital for other reasons. And finally, some people categorized as having died “from COVID” may have died “with COVID” instead (i.e., COVID was not a contributing cause of death).

All of this could be true, but people that strenuously push this narrative while excluding other factors remind me of someone I sat next to on Amtrak. His dog-eared copy of *The Fountainhead* made it clear he had read it too many times, limiting his ability to synthesize any information that contradicted his own, and preventing him from understanding why someone else would see things a different way.

- Yes, some PCR equipment is calibrated to levels that identify both present and past infections, resulting in an exaggerated measure of current infectiousness; PCR equipment should ideally be standardized to avoid unnecessary isolation and shutdowns. But PCR tests are the only way to easily monitor community spread, and are useful as a policy indicator given their high correlation with hospitalizations (the median state correlation of reported COVID infections with COVID hospitalizations is 80%)
- While there may be some hospitalizations that are counted as COVID-related when they really aren’t, my contacts at Johns Hopkins tell me in practice, at a national level, that this is a very small number
- There are mortality errors in both directions: people who died from COVID and weren’t counted, and people who didn’t die from COVID and were counted that way. We can avoid debating mortality classification entirely by looking at “excess deaths”. As shown below, US mortality has been consistently higher than the excess death threshold, and daily US COVID deaths are still 15x-20x higher per person than in Europe
- Furthermore, for my benefit and for yours, please do not focus solely on mortality risks. There are well-documented long-term health risks that some COVID survivors face (see page 3) which should also affect public policy decisions. To exclude them from the narrative is disingenuous at best
- Stop minimizing COVID risks by making too much out of a limited T-cell study from Sweden. The number of people the authors found who appeared to recover from COVID without antibodies: 3. Yes, three. In other words, there is no robust evidence (yet) that T-cells can eradicate COVID on their own without the benefit of antibodies, nor is there evidence that individuals whose T-cells are responding to COVID are somehow not contagious, nor does anyone know if T-cells confer long-term immunity. The consensus is that T-cells may help shorten the course of the disease and its severity, which is good news on its own. Shane Crotty’s work at the La Jolla Institute of Immunology is the gold standard on this topic.

---

14 Some equipment uses 35-40 cycles to determine PCR test positivity, which may pick up trace amounts of infection in people who are most likely not contagious any more, and at the tail end of infection. Something like 30-32 cycles might make more sense if the goal is to identify currently contagious individuals. “High-cycle” PCR tests are best used when frequently testing the same individuals to monitor the progression of the disease, to confirm whether the patient is in the very early (infectious) or late (non-infectious) stage. However, in a recent paper from the UK health system, 8% of samples at cycles above 35 were still infectious.

15 “Your coronavirus test is positive. Maybe it shouldn’t be”, NYT, August 29, 2020

16 Some universities measure virus content in dorm wastewater as an early warning signal, used in conjunction with testing, isolation and contact tracing. More widespread adoption of antigen testing in combination with PCR tests would also improve the process of identifying truly contagious individuals.
**Update on anti-viral, immunomodulator and corticosteroid trials**

**Dexamethasone (corticosteroid).** Dexamethasone is a steroid which reduces inflammation (typically used to treat asthma and arthritis), and has now been shown to minimize effects of cytokine storms\(^\text{17}\) of severely infected patients. Compared to monoclonal antibodies and immune-modulators, they are **generally much cheaper and also readily available.** Results from the UK “Recovery” trial:

- Randomized, controlled trial of 2,104 patients in treatment group vs 4,321 in control group
- Reduced deaths from 40% to 28% in ventilated patients, and reduced the risk of death from 25% to 20% in patients receiving oxygen only; no benefit for patients not requiring respiratory support

**Remdesivir (anti-viral).** Modest benefits but only for patients in the earlier stages of disease.

- The New England Journal of Medicine published the final results of a 1000-patient randomized, double-blind controlled trial conducted by the NIH.\(^\text{18}\) The study showed Remdesivir reduced time to recovery from 13-18 days in the control group to 9-11 days in the group receiving Remdesivir, and reduced mortality from 15.2% to 11.4%. The benefit of Remdesivir was more pronounced when given to patients earlier in the illness, for example to those receiving oxygen but not yet on a ventilator. While not a “miracle drug”, the NEJM study showed that Remdesivir may provide modest benefits for higher-risk patients when administered in early stages

- However, interim results from the WHO’s “Solidarity” trial concluded that Remdesivir has no benefit in reducing mortality, recovery time or ventilation based on a study of 2,700 hospitalized patients receiving it. In the WHO trials, both treatment and control groups had mortality rates of around 11%. Our sources point out that the NIH/NEJM study had fewer patients on oxygen and ventilation in its treatment group than the WHO study, suggesting the NIH results could be more similar to the WHO study if both treatment groups had the same characteristics (i.e., the NIH/NEJM study concentrated on less sick patients).

- Remdesivir is given intravenously rather than orally, so it would only be used in hospital settings, which implies a narrower healthcare impact than drugs that can be delivered on an outpatient basis. Gilead is currently working on an inhalable Remdesivir treatment and subcutaneous injections as well, which would broaden the scope of potential uses

**Tocilizumab (immunomodulator).** This FDA-approved drug treats rheumatoid arthritis and cytokine release syndrome. A French study showed that Tocilizumab reduced deaths and the need for ventilators, and in China, Tocilizumab is included in COVID treatment guidelines. In June 2020, a U. Michigan Tocilizumab trial found a 45% lower likelihood of death compared to control group, a higher % of discharged patients and hospitalized patients not requiring ventilation; and appears to dampen “cytokine storm” severity. The study also noted that Tocilizumab suppresses the immune system, which increases risk of infection. The treatment group was twice as likely to develop a further lung infection (generally bacterial pneumonia).

The latest results come from the REMAP-CAP study in Europe which involves more than 3,900 COVID patients. Patients receiving tocilizumab and a second immunomodulator called sarilumab experienced a reduced risk of death by 24% when administered within 24 hours of entering intensive care.

---

17 Some COVID-19 fatalities experienced **sudden multiple organ failure.** Doctors don’t know yet if that’s because of the viral infection itself, or because of immune system damage caused by a “cytokine storm”, which is a large, rapid release of cytokines into the blood as a result of viral infections or immunotherapy. From oncology doctors at Washington University in St. Louis: “we believe that there is increasing evidence that cytokine storm syndrome is occurring co-incident with the progressive pneumonia and in severe cases may be driving the pathology and increasing the risk of death above and beyond what would be expected by the viral infection by itself”.

**Interferon beta (anti-viral).** In double-blind placebo controlled trials with 50 patients, nebulized interferon reduced ventilation by 80%. Patients were 2-3x more likely to resume everyday activities, and average time in hospitals was reduced by a third.

**Favipiravir (anti-viral).** Fujifilm’s Phase III trials of 156 COVID patients in Japan demonstrated reduced recovery times for COVID-19 patients with non-severe symptoms. More trials are underway in the US, UK and India. This drug is an existing flu treatment first approved in Japan in 2014.

**Ravulizumab-cwbz (immunomodulator).** Phase III trials are ongoing in COVID patients with severe pneumonia or acute respiratory distress syndrome. Preclinical data demonstrated reduced lung inflammation in animals with pneumonia.

**Apilimod (immunomodulator).** The drug showed promise inhibiting COVID in vitro as per a recent *Nature* paper that analyzed 12,000 possible compounds. Al Therapeutics and Yale University announced a randomized, double-blind placebo-controlled Phase II trial with 142 patients. Like other immunomodulators, Apilimod may impair immune functions even as it protects against the virus, so that will be an important outcome to monitor from future trials.

**Chloroquine/hydroxychloroquine (anti-viral):** In April 2020, an NIH panel recommended against the use of HCQ and azithromycin to treat COVID patients. In June, the US Food and Drug Administration revoked its emergency use authorization for hydroxychloroquine and chloroquine for treatment of Covid-19. A case study in bad science, bad medicine, bad reporting and according to some accounts, bad behavior as well.¹⁹

**Convalescent plasma and monoclonal antibody therapy**

Convalescent plasma refers to virus-neutralizing antibodies harvested from recovered patients to treat infected patients and vulnerable populations. It was used during the Victorian era before antibiotics to treat meningitis & pneumonia by injecting bacteria into horses and harvesting horse serum. Convalescent plasma is currently used to treat immuno-deficient individuals against measles and mumps, and was successfully used to treat patients during both SARS in 2002 and the 2009-2010 H1N1 influenza pandemic. Like antivirals and vaccines, convalescent plasma applied to COVID-19 will require clinical trials to demonstrate both safety and efficacy.

**UPDATES:**

- **January 16, 2021:** The “Recovery” trial suspended its convalescent plasma study after it showed no benefits for hospitalized patients. Analysis of 1,873 deaths in a study of 10,400 UK patients showed the treatment made "no significant difference". In the group treated with convalescent plasma, 18% of patients died within 28 days - the same figure for the group given standard treatment.

- **January 29, 2021:** A randomized trial of convalescent plasma for 940 hospitalized adults (CONCOR-1) stopped enrollment after the independent data safety monitoring committee determined the study is unlikely to demonstrate a benefit of convalescent plasma even if more patients were enrolled.

- **February 25, 2021:** An interim analysis of the National Heart, Lung and Blood Institute convalescent plasma trial concluded that, while its treatment of 500 mild to moderate COVID patients caused no harm, it was unlikely to benefit the patients enrolled.

**The details:** An August 2020 Mayo Clinic study reported that mortality rates were lower for patients given convalescent plasma within 3 days of COVID diagnosis compared to patients receiving it after 3 days (7-day mortality rates 8.7% vs 11.9%, 30-day mortality rates 21.6% vs 26.7%). However, in February 2021, researchers in Argentina published the results of their randomized controlled trial of convalescent plasma. 228 hospitalized patients received convalescent plasma treatment and 105 patients were assigned to a placebo. The study found that there was no significant difference in clinical outcomes between the treatment group and the placebo group.

Rockefeller University released a study on the dynamics of convalescent plasma antibodies. They found that most donors do not have high levels of antibodies, and that for one third of donors, neutralizing antibodies were undetectable, rendering their plasma contributions worthless. Furthermore, only 1% of donors showed “elite” high-level neutralizing antibodies. However, elite donor antibodies are sufficiently powerful so that even when diluted 1000-fold, the plasma can still neutralize the virus and last for several months. As a result, Rockefeller scientists initiated clinical trials in January 2021 of a new monoclonal antibody drug created by cloning these elite antibodies.
Like convalescent plasma, **monoclonal antibody therapy** (mAb) involves infusion of antibodies with the goal of preventing infected people becoming ill, and preventing the ill from dying. How do mAb work? They are engineered with the goal of being more precise than convalescent plasma: neutralize the infectivity of SARS-CoV-2 by binding specifically to the spike protein that enables it to enter human cells. A likely treatment regimen could contain 2 or 3 different mAbs. While convalescent plasma relies on antibodies harvested from recovered individuals, mAb can be harvested from recovered humans, from mice genetically modified to have the immune system of a human being, via genetic engineering or from advanced cell cultures. While mAb are used to treat cancer and autoimmune diseases, few have been developed for infectious diseases. However, mAb worked against Ebola, several companies are entering human clinical mAb trials:

- **Regeneron (REGN-COV2).** Phase II/III results from Regeneron’s trial of 800 non-hospitalized participants found that the treatment reduced the viral load by 10-fold in the treatment group compared to the placebo, and reduced COVID-related medical visits by 57% through day 29. Final Phase III data indicated that the drug reduced risk of hospitalization or death by 70%. Phase III data also show that, among infected asymptomatic individuals, the treatment reduced the risk of progressing to symptomatic COVID by 76% three days after treatment. Regeneron received Emergency Use Authorization in November 2020 to be used in outpatient settings for people with mild to moderate COVID who are at high risk for hospitalization or developing a severe case. It is not authorized for patients who are already hospitalized or require oxygen. A small study of 1,500 participants also tested Regeneron as a preventative treatment among people living in the same household as COVID-infected individuals. The study found that the treatment, which is administered by injection, was 81% effective at preventing symptomatic infection. Preprints from Columbia and NYU showed the mAb cocktail retained efficacy against the B.1.351 variant, though with a 9-fold reduction in neutralizing activity.

- **Eli Lilly/AbCellera (LY-COV55).** Phase II/III trials in 450 recently diagnosed individuals showed that mAb treatment reduced hospitalization rates to 1.7% compared to 6% in the placebo group. Final Phase III results showed the treatment demonstrated 87% efficacy in preventing hospitalizations and deaths among high-risk patients with mild to moderate infections. Eli Lilly received Emergency Use Authorization from the FDA in November 2020 for use of the treatment in high-risk patients in outpatient settings, to be administered in newly infected people within 10 days of developing symptoms. However, in March 2021, the FDA announced that the monoclonal antibody would no longer be distributed due to concerns about efficacy against new variants of concern in the U.S. A recent study from Columbia University showed that, while the mAb retained potency against the B.1.1.7 variant, neutralization of B.1351 was “completely or markedly abolished.”

- **GSK/Vir (VIR-7831).** In March 2021, GSK/Vir’s Phase III trial of its monoclonal antibody demonstrated 85% efficacy in reducing hospitalization and death among 583 high-risk participants with mild or moderate COVID. A forthcoming in vitro study from GSK/Vir found that the treatment demonstrates efficacy against the UK, South Africa and Brazil variants. Like other monoclonal antibodies, the treatment must be administered intravenously to patients early in the disease, though the company is initiating Phase III trials to test efficacy both as an intramuscular injection and as a preventative measure against COVID in high-risk adults. Based on these results, the companies are seeking Emergency Use Authorization from the FDA and global regulatory authorities.

**The advantages of mAb:** can be used both as acute therapy for COVID patients and as a prophylactic for frontline health care workers. The disadvantages: higher cost than vaccines; harder to produce at scale since a large dose of recombinant proteins might be needed since your body isn’t making them for you; and temporary.
Possible benefits of anticoagulants, statins and ACE inhibitors for infected patients

Healthcare professionals have noticed a range of unconnected vascular phenomena that aren’t seen with SARS-CoV-1 or H1N1. Medical directors at Brigham and Women’s Hospital Heart and Vascular Center in Boston believe that COVID is a “vasculotropic” disease, and that SARS-CoV-2 can infect endothelial cells that line the inside of blood vessels (these cells protect the cardiovascular system and release proteins that influence everything from blood clotting to the immune response):

• Damage to endothelial cells causes inflammation in blood vessels, which can cause accumulated plaque to rupture, causing a heart attack. Blood vessel damage could also explain why people with pre-existing conditions like high blood pressure, high cholesterol, diabetes, and heart disease are at a higher risk for severe complications from a virus that’s supposed to just infect the lungs. All of those diseases cause endothelial cell damage, and additional damage in blood vessels caused by the infection could result in more severe complications and death.

• This could explain why ventilation often isn’t enough to help patients breathe better. Moving air into the lungs via ventilation can help, but exchange of oxygen and carbon dioxide in the blood is just as important to provide the rest of the body with oxygen; that requires healthy blood vessels in and around the lungs.

• If COVID is a vascular disease, ACE inhibitors and statins might help protect against endothelial cell damage. However, so far, most studies we have seen assess the outcomes for COVID patients that were already taking statins and ACE inhibitors (not studies on such treatments being applied for the first time to infected COVID patients).

  • A UCSD study found that prior statin use was associated with a lower risk of developing severe COVID disease, and a faster time to recovery with patients with severe disease. Similar results were found in studies from Oxford, the Universitat Rovira i Virgili/Pere Virgili Institut (Spain) and the Policlinico di Modena Hospital (Italy).

• Blood thinners have been shown to help as well. A May report in the Journal of the American College of Cardiology analyzed medical records of 2,773 COVID-19 patients in NYC hospitals. The study was initiated after doctors realized that COVID can result in life-threatening blood clots. Notable findings: survival rates for 395 intubated patients treated with anticoagulants were 62% compared to 29% for those who were not.

  • However, anticoagulation is controversial and a very delicate balance. COVID physicians we spoke with cite negative side effects such as bleeding (oftentimes brain bleeds that were not recognized until the patients were being considered for extubation), and benefits given the large number of strokes in patients hospitalized with COVID that anticoagulants can prevent. The protocols and research on anticoagulants for COVID patients is still a work in progress.

---


IMPORTANT INFORMATION

The views, opinions and estimates expressed herein constitute Michael Cremo’s judgement based on current market conditions and are subject to change without notice. Information herein may differ from those expressed by other areas of J.P. Morgan. This information in no way constitutes J.P. Morgan Research and should not be treated as such.

The views contained herein are not to be taken as advice or a recommendation to buy or sell any investment in any jurisdiction, nor is it a commitment from J.P. Morgan or any of its subsidiaries to participate in any of the transactions mentioned herein. Any forecasts, figures, opinions or investment techniques and strategies set out are for information purposes only, based on certain assumptions and current market conditions and are subject to change without prior notice. All information presented herein is considered to be accurate at the time of production. This material does not contain sufficient information to support an investment decision and it should not be relied upon by you in evaluating the merits of investing in any securities or products. In addition, users should make an independent assessment of the legal, regulatory, tax, credit and accounting implications and determine, together with their own professional advisers, if any investment mentioned herein is believed to be suitable to their personal goals. Investors should ensure that they obtain all available relevant information before making any investment. It should be noted that investment involves risks, the value of investments and the income from them may fluctuate in accordance with market conditions and taxation agreements and investors may not get back the full amount invested. Both past performance and yields are not reliable indicators of current and future results.

Non-affiliated entities mentioned are for informational purposes only and should not be construed as an endorsement or sponsorship of J.P. Morgan Chase & Co. or its affiliates.

For J.P. Morgan Asset Management Clients:

J.P. Morgan Asset Management is the brand for the asset management business of JPMorgan Chase & Co. and its affiliates worldwide.

To the extent permitted by applicable law, we may record telephone calls and monitor electronic communications to comply with our legal and regulatory obligations and internal policies. Personal data will be collected, stored and processed by J.P. Morgan Asset Management in accordance with our privacy policies at https://am.jpmorgan.com/global/privacy.

ACCESSIBILITY

For U.S. only: If you are a person with a disability and need additional support in viewing the material, please call us at 1-800-343-1113 for assistance.

This communication is issued by the following entities:

In the United States, by J.P. Morgan Investment Management Inc. or J.P. Morgan Alternative Asset Management, Inc., both regulated by the Securities and Exchange Commission; in Latin America, for intended recipients’ use only, by local J.P. Morgan entities, as the case may be; in Canada, for institutional clients’ use only, by JPMorgan Asset Management (Canada) Inc., which is a registered Portfolio Manager and Exempt Market Dealer in all Canadian provinces and territories except the Yukon and is also registered as an Investment Fund Manager in British Columbia, Ontario, Quebec and Newfoundland and Labrador. In the United Kingdom, by JPMorgan Asset Management (UK) Limited, which is authorized and regulated by the Financial Conduct Authority; in other European jurisdictions, by JPMorgan Asset Management (Europe) S.à r.l. In Asia Pacific (“APAC”), by the following issuing entities and in the respective jurisdictions in which they are primarily regulated: JPMorgan Asset Management (Asia Pacific) Limited, or JPMorgan Funds (Asia) Limited, or JPMorgan Asset Management Real Assets (Asia) Limited, each of which is regulated by the Securities and Futures Commission of Hong Kong; JPMorgan Asset Management (Singapore) Limited (Co. Reg. No. 197601586K), which this advertisement or publication has not been reviewed by the Monetary Authority of Singapore; JPMorgan Asset Management (Taiwan) Limited; JPMorgan Asset Management (Japan) Limited, which is a member of the Investment Trusts Association, Japan, the Japan Investment Advisers Association, Type II Financial Instruments Firms Association and the Japan Securities Dealers Association and is regulated by the Financial Services Agency (registration number “Kanto Local Finance Bureau (Financial Instruments Firm) No. 330”); in Australia, to wholesale clients only as defined in section 761A and 761G of the Corporations Act 2001 (Commonwealth), by JPMorgan Asset Management (Australia) Limited (ABN 55143832080) (AFSL 376919). For all other markets in APAC, to intended recipients only.

For J.P. Morgan Private Bank Clients:

ACCESSIBILITY

J.P. Morgan is committed to making our products and services accessible to meet the financial services needs of all our clients. Please direct any accessibility issues to the Private Bank Client Service Center at 1-866-265-1727.

LEGAL ENTITY, BRAND & REGULATORY INFORMATION

In the United States, bank deposit accounts and related services, such as checking, savings and bank lending, are offered by JPMorgan Chase Bank, N.A. Member FDIC. JPMorgan Chase Bank, N.A. and its affiliates (collectively “JPMCB”) offer investment products, which may include bank-managed investment accounts and custody, as part of its trust and fiduciary services. Other investment products and services, such as brokerage and advisory accounts, are offered through J.P. Morgan Securities LLC (“JPMMS”), a member of FINRA and SIPC. Annuities are made available through Chase Insurance Agency, Inc. (CIA), a licensed insurance agency, doing business as Chase Insurance Agency Services, Inc. in Florida. JPMCB, JPMMS and CIA are affiliated companies under the common control of JPMorgan Chase & Co. Products not available in all states.

In Luxembourg, this material is issued by J.P. Morgan Bank Luxembourg S.A. (JPMBL), with registered office at European Bank and Business Centre, 6 route de Treves, L-2633, Senningerberg, Luxembourg. R.C.S Luxembourg B10.958. Authorized and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg S.A. is authorized as a credit institution in accordance with the Law of 5th April 1993. In the United Kingdom, this material is issued by J.P. Morgan Bank Luxembourg S.A.– London Branch. Prior to Brexit,(Brexit meaning that the UK leaves the European Union under Article 50 of the Treaty on European Union, or, if later, loses its ability to passport financial services between the UK and the remainder of the EEA), J.P. Morgan Bank Luxembourg S.A.– London Branch is subject to limited regulation by the Financial Conduct Authority and the Prudential Regulation Authority. Details about the extent of our regulation by the Financial Conduct Authority and the Prudential Regulation Authority are available from us on request. In the event of Brexit, in the UK, J.P. Morgan Bank Luxembourg S.A.– London Branch is authorised by the Prudential Regulation Authority, subject to regulation by the Financial Conduct Authority and limited regulation by the Prudential Regulation Authority. Details about the extent of our regulation by the Prudential Regulation Authority are available from us on request. In Spain, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Sucursal en España, with registered office at Paseo de la Castellana, 31, 28046 Madrid, Spain. J.P. Morgan Bank Luxembourg S.A., Sucursal en España is registered under number 1516 within the administrative registry of the Bank of Spain and supervised by the Spanish Securities Market Commission (CNMV). In Germany, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Frankfurt Branch, registered office at Taunustor 1 (TaunusTurm), 60310 Frankfurt, Germany, jointly supervised by the Commission de Surveillance du Secteur Financier (CSSF) and the European Central Bank (ECB), and in certain areas also supervised by the Bundesanstalt für Finanzdienstleistungsaufsicht (BaFin). In Italy, this material is distributed by J.P. Morgan Bank Luxembourg S.A.– Milan Branch, registered office at Via Catena Auladiberto 4, Milan 20121, Italy and regulated by Bank of Italy and the Commissione Nazionale per le Società e la Borsa (CONSOB). In the Netherlands, this material is distributed by J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch, with registered office at World Trade

20
Centre, Tower B, Strawinskylaan 1135, 1077 XX, Amsterdam, The Netherlands. J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is authorised and regulated by the Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF in Luxembourg; J.P. Morgan Bank Luxembourg S.A., Amsterdam Branch is also authorised and supervised by De Nederlandsche Bank (DNB) and the Autoriteit Financiële Markten (AFM) in the Netherlands. Registered with the Kamer van Koophandel as a branch of J.P. Morgan Bank Luxembourg S.A. under registration number 71651845. In Denmark, this material is distributed by J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. with registered office at Kalvebod Brygge 39-41, 1560 København V, Denmark. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg, Copenhagen Br, filial af J.P. Morgan Bank Luxembourg S.A. is also subject to the supervision of Finanstilsynet (Danish FSA) and registered with Finanstilsynet as a branch of J.P. Morgan Bank Luxembourg S.A. under code 29009. In Sweden, this material is distributed by J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial, with registered office at Hamngatan 15, Stockholm, 11147, Sweden. J.P. Morgan Bank Luxembourg S.A. - Stockholm Bankfilial is authorised and regulated by Commission de Surveillance du Secteur Financier (CSSF) and jointly supervised by the European Central Bank (ECB) and the CSSF. J.P. Morgan Bank Luxembourg, Stockholm Branch is also subject to the supervision of Finansinspektionen (Swedish FSA). Registered with Finansinspektionen as a branch of J.P. Morgan Bank Luxembourg S.A. In France, this material is distributed by JPMorgan Chase Bank, N.A. ("JPMCB"), Paris branch, which is regulated by the French banking authorities Autorité de Contrôle Prudentiel et de Résolution and Autorité des Marchés Financiers. In Switzerland, this material is distributed by J.P. Morgan (Suisse) SA, which is regulated in Switzerland by the Swiss Financial Market Supervisory Authority (FINMA).

In Hong Kong, this material is distributed by JPMCB, Hong Kong branch. JPMCB, Hong Kong branch is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission of Hong Kong. In Hong Kong, we will cease to use your personal data for our marketing purposes without charge if you so request. In Singapore, this material is distributed by JPMCB, Singapore branch. JPMCB, Singapore branch is regulated by the Monetary Authority of Singapore. Dealing and advisory services and discretionary investment management services are provided to you by JPMCB, Hong Kong/Singapore branch (as notified to you). Banking and custody services are provided to you by JPMCB Singapore Branch. The contents of this document have not been reviewed by any regulatory authority in Hong Kong, Singapore or any other jurisdictions. This advertisement has not been reviewed by the Monetary Authority of Singapore. JPMorgan Chase Bank, N.A., a national banking association chartered under the laws of the United States, and as a body corporate, its shareholder’s liability is limited.

JPMorgan Chase Bank, N.A. (JPMCBNA) (ABN 43 074 112 011/AFS Licence No: 238367) is regulated by the Australian Securities and Investment Commission and the Australian Prudential Regulation Authority. Material provided by JPMCBNA in Australia is to “wholesale clients” only. For the purposes of this paragraph the term “wholesale client” has the meaning given in section 761G of the Corporations Act 2001 (Cth). Please inform us if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

JPMorgan Chase Bank, N.A. is a registered foreign company (overseas) (ARBN 109293610) incorporated in Delaware, U.S.A. Under Australian financial services licensing requirements, carrying on a financial services business in Australia requires a financial service provider, such as J.P. Morgan Securities LLC (JPMIL), to hold an Australian Financial Services Licence (AFSL), unless an exemption applies. JPMIS is exempt from the requirement to hold an AFSL under the Corporations Act 2001 (Cth) (Act) in respect of financial services it provides to you, and is regulated by the SEC, FINRA and CFTC under US laws, which differ from Australian laws. Material provided by JPMIS in Australia is to “wholesale clients” only. The information provided in this material is not intended to be, and must not be, distributed or passed on, directly or indirectly, to any other class of persons in Australia. For the purposes of this paragraph the term “wholesale client” has the meaning given in section 761G of the Act. Please inform us immediately if you are not a Wholesale Client now or if you cease to be a Wholesale Client at any time in the future.

This material has not been prepared specifically for Australian investors. It:
may contain references to dollar amounts which are not Australian dollars;
may contain financial information which is not prepared in accordance with Australian law or practices;
may not address risks associated with investment in foreign currency denominated investments; and
does not address Australian tax issues.

With respect to countries in Latin America, the distribution of this material may be restricted in certain jurisdictions. We may offer and/or sell to you securities or other financial instruments which may not be registered under, and are not the subject of a public offering under, the securities or other financial regulatory laws of your home country. Such securities or instruments are offered and/or sold to you on a private basis only. Any communication by us to you regarding such securities or instruments, including without limitation the delivery of a prospectus, term sheet or other offering document, is not intended by us as an offer to sell or a solicitation of an offer to buy any securities or instruments in any jurisdiction in which such an offer or a solicitation is unlawful. Furthermore, such securities or instruments may be subject to certain regulatory and/or contractual restrictions on subsequent transfer by you, and you are solely responsible for ascertaining and complying with such restrictions. To the extent this content makes reference to a fund, the Fund may not be publicly offered in any Latin American country, without previous registration of such fund’s securities in compliance with the laws of the corresponding jurisdiction. Public offering of any security, including the shares of the Fund, without previous registration at Brazilian Securities and Exchange Commission—CVM is completely prohibited. Some products or services contained in the materials might not be currently provided by the Brazilian and Mexican platforms.

References to “J.P. Morgan” are to JPM, its subsidiaries and affiliates worldwide. “J.P. Morgan Private Bank” is the brand name for the private banking business conducted by JPM.

This material is intended for your personal use and should not be circulated to or used by any other person, or duplicated for non-personal use, without our permission. If you have any questions or no longer wish to receive these communications, please contact your J.P. Morgan representative.

© 2020 JPMorgan Chase & Co. All rights reserved.